Bill Fleming

Bill is Chief Financial Officer at Oxford University spinout and precision medicine cancer company, Celleron Therapeutics Ltd, having joined the team in 2018.  A law graduate from Cambridge University and qualified ACMA with 30 years of experience, Bill spent his early career in large multinational companies including Lafarge, BAE Systems and Bayer.  Focussed on Life Sciences since the year 2000, Bill has previously held CFO/FD positions at Visible Genetics, Oxitec, Grey Wolf Therapeutics, Ultromics, The Electrospinning Company, and SynOx Therapeutics.  Bill joined ITSIG in 2016, served as a director of OBN from 2017 and as Chairman until 2020. Bill has extensive financial experience in Biotech and Life Sciences supporting start-ups, spinouts and SME’s.